INTERVENTION 1:	Intervention	0
GTx-024 1 mg	Intervention	1
[Not Specified]	Intervention	2
INTERVENTION 2:	Intervention	3
GTx-024 3 mg	Intervention	4
[Not Specified]	Intervention	5
Inclusion Criteria:	Eligibility	0
To be eligible for participation in this study, subjects must meet all of the following criteria:	Eligibility	1
have been diagnosed with Stage 2, 3 or 4 non-small cell lung cancer or Stage 2, 3 or 4 colorectal cancer or non-hodgkin's lymphoma or chronic lymphocytic leukemia or Stage 3 or 4 breast cancer.	Eligibility	2
lung cancer	DOID:1324	56-67
colorectal cancer	DOID:9256	87-104
lymphoma	HP:0002665,DOID:0060058	122-130
chronic lymphocytic leukemia	DOID:1040	134-162
breast cancer	DOID:1612	179-192
be prior to initiation of or between cycles of chemotherapy.	Eligibility	3
have experienced greater than or equal to 2% weight loss from the highest patient reported weight in the 6 months prior to screening for Protocol G200502 (Wt = body weight)	Eligibility	4
weight loss	HP:0001824	45-56
patient	HADO:0000008,OAE:0001817	74-81
body weight	CMO:0000012	160-171
% weight loss = (Wt at screening - highest Wt in last 6 months) / highest Wt in last 6 months x 100%	Eligibility	5
weight loss	HP:0001824	2-13
x	LABO:0000148	94-95
If surgery is part of the cancer treatment, screening for this study should be conducted at least 2 weeks (14 days) after surgery.	Eligibility	6
surgery	OAE:0000067	3-10
surgery	OAE:0000067	122-129
part of	BAO:0090002,BFO:0000050	14-21
cancer	DOID:162	26-32
have a life expectancy of >6 months	Eligibility	7
FEMALES - be clinically confirmed as postmenopausal	Eligibility	8
MALES - over 45 years of age	Eligibility	9
age	PATO:0000011	25-28
ECOG score 1	Eligibility	10
Exclusion Criteria:	Eligibility	11
Subjects with any of the following will NOT be eligible for enrollment in this study:	Eligibility	12
history of active/uncontrolled congestive heart failure, chronic hepatitis, hepatic cirrhosis, or HIV infection	Eligibility	13
history	BFO:0000182	0-7
congestive heart failure	HP:0001635,DOID:6000	31-55
chronic hepatitis	HP:0200123,DOID:2237	57-74
cirrhosis	HP:0001394	84-93
Cardiovascular: No uncontrolled hypertension	Eligibility	14
hypertension	HP:0000822,DOID:10763	32-44
Positive screen for Hepatitis B consisting of HBsAg (Hepatitis B Surface Antigen), anti-HCV (Hepatitis C Antibody), hepatitis A antibody IgM, or HIV	Eligibility	15
hepatitis b	DOID:2043	20-31
hepatitis b	DOID:2043	53-64
antigen	CHEBI:59132	73-80
hepatitis c	DOID:1883	93-104
antibody	GO:0042571,BAO:0000502	105-113
antibody	GO:0042571,BAO:0000502	128-136
hepatitis a	DOID:12549	116-127
igm	BAO:0002612	137-140
Currently taking testosterone, OXANDRIN® (oxandrolone), testosterone-like agents (such as DHEA, androstenedione, and other androgenic compounds, including herbals), or antiandrogens (Please note that previous therapy with testosterone and testosterone-like agents is acceptable with a 30 day wash-out. However, if the previous testosterone therapy was a long-term depot, within the past 6 months, the site should call the medical monitor for this study to determine appropriate washout period.)	Eligibility	16
testosterone	CHEBI:17347	17-29
testosterone	CHEBI:17347	56-68
testosterone	CHEBI:17347	222-234
testosterone	CHEBI:17347	239-251
testosterone	CHEBI:17347	327-339
oxandrolone	CHEBI:7820	42-53
day	UO:0000033	288-291
site	BFO:0000029	401-405
Currently taking megestrol acetate (MEGACE®), dronabinol (MARINOL®), or any prescription medication intended to increase appetite or treat unintentional weight loss	Eligibility	17
megestrol acetate	CHEBI:6723	17-34
increase	BAO:0001251	112-120
weight loss	HP:0001824	153-164
Outcome Measurement:	Results	0
The Efficacy of GTx-024 on Total Body Lean Mass.	Results	1
efficacy	BAO:0000656	4-12
Change in total body lean mass as measured by dual energy x-ray absorptiometry (DEXA)from baseline to 4 months.	Results	2
Time frame: Baseline to Four Months	Results	3
time	PATO:0000165	0-4
Results 1:	Results	4
Arm/Group Title: GTx-024 1 mg	Results	5
Arm/Group Description: [Not Specified]	Results	6
Overall Number of Participants Analyzed: 32	Results	7
Median (Full Range)	Results	8
median	BAO:0002174	0-6
range	LABO:0000114	13-18
Unit of Measure: kg  1.55        (-2.06 to 12.64)	Results	9
Results 2:	Results	10
Arm/Group Title: GTx-024 3 mg	Results	11
Arm/Group Description: [Not Specified]	Results	12
Overall Number of Participants Analyzed: 34	Results	13
Median (Full Range)	Results	14
median	BAO:0002174	0-6
range	LABO:0000114	13-18
Unit of Measure: kg  0.98        (-4.84 to 11.54)	Results	15
Adverse Events 1:	Adverse Events	0
Total: 14/53 (26.42%)	Adverse Events	1
Anaemia 3/53 (5.66%)	Adverse Events	2
Febrile Neutropenia 2/53 (3.77%)	Adverse Events	3
neutropenia	HP:0001875,DOID:1227	8-19
Neutropenia 1/53 (1.89%)	Adverse Events	4
neutropenia	HP:0001875,DOID:1227	0-11
Pancytopenia 0/53 (0.00%)	Adverse Events	5
pancytopenia	HP:0001876,DOID:12450	0-12
Thrombocytopenia 0/53 (0.00%)	Adverse Events	6
thrombocytopenia	HP:0001873,DOID:1588	0-16
Atrial Fibrillation 1/53 (1.89%)	Adverse Events	7
atrial fibrillation	HP:0005110,DOID:0060224	0-19
Myocardial infarction 1/53 (1.89%)	Adverse Events	8
myocardial infarction	HP:0001658,DOID:5844	0-21
Diarrhoea 1/53 (1.89%)	Adverse Events	9
Dysphagia 0/53 (0.00%)	Adverse Events	10
dysphagia	HP:0002015	0-9
gastric ulcer perforation 0/53 (0.00%)	Adverse Events	11
gastric ulcer	HP:0002592,DOID:10808	0-13
lower gastrointestinal haemorrhage 0/53 (0.00%)	Adverse Events	12
Adverse Events 2:	Adverse Events	13
Total: 15/54 (27.78%)	Adverse Events	14
Anaemia 0/54 (0.00%)	Adverse Events	15
Febrile Neutropenia 0/54 (0.00%)	Adverse Events	16
neutropenia	HP:0001875,DOID:1227	8-19
Neutropenia 1/54 (1.85%)	Adverse Events	17
neutropenia	HP:0001875,DOID:1227	0-11
Pancytopenia 0/54 (0.00%)	Adverse Events	18
pancytopenia	HP:0001876,DOID:12450	0-12
Thrombocytopenia 1/54 (1.85%)	Adverse Events	19
thrombocytopenia	HP:0001873,DOID:1588	0-16
Atrial Fibrillation 0/54 (0.00%)	Adverse Events	20
atrial fibrillation	HP:0005110,DOID:0060224	0-19
Myocardial infarction 0/54 (0.00%)	Adverse Events	21
myocardial infarction	HP:0001658,DOID:5844	0-21
Diarrhoea 0/54 (0.00%)	Adverse Events	22
Dysphagia 0/54 (0.00%)	Adverse Events	23
dysphagia	HP:0002015	0-9
gastric ulcer perforation 0/54 (0.00%)	Adverse Events	24
gastric ulcer	HP:0002592,DOID:10808	0-13
lower gastrointestinal haemorrhage 1/54 (1.85%)	Adverse Events	25
